Related references
Note: Only part of the references are listed.Central abdominal uptake of indium-111 capromab pendetide (ProstaScint) predicts for poor prognosis in patients with prostate cancer
Michael K. Haseman et al.
UROLOGY (2007)
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression
Sven Perner et al.
HUMAN PATHOLOGY (2007)
Rectal morbidity after permanent prostate brachytherapy with dose escalation to biologic target volumes identified by SPECT/CT fusion
Rodney J. Ellis et al.
BRACHYTHERAPY (2007)
Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer
Suneel N. Nagda et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Cancer statistics, 2007
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2007)
Biochemical disease-free survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide
Rodney J. Ellis et al.
BRACHYTHERAPY (2007)
Management of advanced prostate cancer after first-line chemotherapy
DR Berthold et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Geographic and socioeconomic variation in the treatment of prostate cancer
TL Krupski et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Pilot trial of unlabeled and indium-111-labeled anti-prostate-specific membrane antigen antibody J591 for castrate metastatic prostate cancer
MJ Morris et al.
CLINICAL CANCER RESEARCH (2005)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
ProstaScint (capromab pendetide) imaging using hybrid gamma camera-CT technology
TZ Wong et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2005)
Spread of prostate carcinoma to the perirectal lymph node basin - Analysis of 112 rectal resections over a 10-year span for primary rectal adenocarcinoma
SK Murray et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2004)
Impact of fusion of indium-III Capromab pendetide volume data sets with those from MRI or CT in patients with recurrent prostate cancer
CJ Schettino et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2004)
The role of 111indium-capromab pendetide imaging for assessing biochemical failure after radical prostatectomy
S Wilkinson et al.
JOURNAL OF UROLOGY (2004)
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
DP Petrylak et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer
IF Tannock et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
N Schülke et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Noninvasive detection of clinically occult lymph-node metastases in prostate cancer
MG Harisinghani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Indium-111-capromab pendetide Radioimmunoscintigraphy and prognosis for durable biochemical response to salvage radiation therapy in men after failed prostatectomy
CT Thomas et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance of cure?
P Bader et al.
JOURNAL OF UROLOGY (2003)
Extended pelvic lymphadenectomy in patients undergoing radical prostatectomy: High incidence of lymph node metastasis
A Heidenreich et al.
JOURNAL OF UROLOGY (2002)
Share Paper
